The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

“We are pleased to initiate patient dosing in this important Phase 2 study, which evaluates VX-01 as a potential early intervention for diabetic retinopathy,” said Alek Safarian, Co-Founder ...

Pars plana vitrectomy is a safe and effective surgery that is essential in the treatment of a variety of posterior segment ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

People with type 2 diabetes who regularly use the supplement glucosamine have a lower risk for microvascular complications ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

Verseon is combining AI with deep quantum modeling, which allows for stronger models of protein-drug interactions. CEO Adityo ...

An eye check up is more than just about finding vision issues. A thorough eye or retinal scan can, in fact, reveal early ...

Detailed price information for Clover Health Investments Corp (CLOV-Q) from The Globe and Mail including charting and trades.